VIRGINIA RETIREMENT SYSTEMS ET Al Invests $1.58 Million in Insulet Corporation $PODD

Posted by on Sep 12th, 2026

VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in Insulet Corporation (NASDAQ:PODD – Free Report) in the 2nd quarter, according to its most recent filing with the SEC. The fund acquired 10,360 shares of the medical instruments supplier’s stock, valued at approximately $1,577,000.

Other large investors have also bought and sold shares of the company. OP Asset Management Ltd bought a new stake in Insulet during the 1st quarter worth about $1,513,000. OneDigital Investment Advisors LLC bought a new position in shares of Insulet in the 2nd quarter valued at about $6,741,000. SEB Asset Management AB bought a new position in shares of Insulet in the 1st quarter valued at about $24,700,000. DNB Asset Management AS increased its position in shares of Insulet by 21.1% in the fourth quarter. DNB Asset Management AS now owns 58,161 shares of the medical instruments supplier’s stock valued at $16,532,000 after acquiring an additional 10,148 shares during the last quarter. Finally, Jupiter Asset Management Ltd. acquired a new stake in shares of Insulet in the fourth quarter valued at about $66,644,000.

Insulet Stock Performance

Shares of PODD stock opened at $131.96 on Friday. Insulet Corporation has a 52 week low of $126.40 and a 52 week high of $354.88. The company has a market capitalization of $9.15 billion, a price-to-earnings ratio of 24.67, a PEG ratio of 1.06 and a beta of 1.08. The company has a 50-day simple moving average of $152.36 and a 200 day simple moving average of $173.92. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.83 and a current ratio of 2.48.

Insulet (NASDAQ:PODD – Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The medical instruments supplier reported $1.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.47 by $0.19. Insulet had a net margin of 12.29% and a return on equity of 29.29%. The firm had revenue of $801.70 million during the quarter, compared to the consensus estimate of $787.39 million. During the same period last year, the business posted $1.17 earnings per share. The business’s revenue for the quarter was up 23.5% compared to the same quarter last year. Insulet has set its FY 2026 guidance at 6.460- EPS. On average, sell-side analysts predict that Insulet Corporation will post 6.51 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on PODD shares. Raymond James Financial reiterated an “outperform” rating and set a $180.00 price objective on shares of Insulet in a research note on Thursday, August 6th. Weiss Ratings downgraded shares of Insulet from a “hold (c-)” rating to a “sell (d+)” rating in a report on Wednesday, June 24th. Robert W. Baird set a $175.00 price target on shares of Insulet in a research report on Thursday, August 6th. The Goldman Sachs Group reiterated a “buy” rating and issued a $205.00 price target on shares of Insulet in a research note on Wednesday, May 27th. Finally, Oppenheimer downgraded shares of Insulet from an “outperform” rating to a “market perform” rating in a research report on Wednesday, August 5th. Fourteen analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $195.40.

Read Our Latest Research Report on PODD

Insulet Company Profile

(Free Report)

Insulet Corporation is a medical device company that develops, manufactures and sells wearable insulin delivery systems for people with insulin-dependent diabetes. Its products are designed to provide an alternative to traditional insulin injections and conventional tubed insulin pumps.

The company’s principal product platform is Omnipod, a tubeless, wearable insulin pump system. Omnipod products include the disposable, wearable Pod and related management and smartphone-based technologies.

Read More

Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Corporation (NASDAQ:PODD – Free Report).

Institutional Ownership by Quarter for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.